Evolving Strategies in Breast Cancer Treatment

This chapter delves into the use of L-acestrin and other therapies as potential treatment options for HR-positive, HER2-negative metastatic breast cancer, emphasizing the significance of patient-specific factors and genetic mutations like ESR1. It discusses the complexities of treatment management, drug resistance, and the impact of ongoing trials like Serena 6, highlighting the importance of monitoring mutations to enhance patient outcomes. Ultimately, the chapter underscores the necessity for innovative approaches to personalize therapy and improve progression-free survival in breast cancer patients.